Skip to main content
Life logoLink to Life
. 2022 Oct 18;12(10):1626. doi: 10.3390/life12101626

Reply to Crimi, C.; Cortegiani, A. Comment on “Liu et al. Application of High-Flow Nasal Cannula in COVID-19: A Narrative Review. Life 2022, 12, 1419”

Cheng-Wei Liu 1,*, Shih-Lung Cheng 1,2
Editors: Olivier Pierrefiche, Katalin Prokai-Tatrai
PMCID: PMC9604714  PMID: 36295061

Thanks for Crimi et al.’s comment [1]. The following is our response to your comment.

We recommend HFNC as a first-line treatment for patients with “severe” COVID-19 in the small discussion chapter of this review article. We are sorry for not giving clear definition of severe COVID-19 in our discussion chapter. The definition of severe COVID-19 here is to use 6–15 L O2/min (FiO2 0.4–0.6) to achieve the target SpO2 (≥90% for nonpregnant patients and ≥92–95% for pregnant patients) [2]. In other words, HFNC may be suggested as a first-line treatment in patients with severe COVID-19 if COT (conventional oxygen therapy) can not meet adequate oxygenation in those patients, and IMV (invasive mechanical ventilation) is not indicated at the time. However, more well-designed RCTs in the future are needed to support this idea.

Indeed, a personalized and stepwise approach is important in treating COVID-19 patients with hypoxemic respiratory failure. Although there is still uncertainty about optimal oxygen strategy in COVID-19 patients with hypoxemic respiratory failure, HFNC may play an important role in a stepwise approach because of its great comfort for the patients.

We have learned much from your comment. Thank you again.

Conflicts of Interest

The authors declare no conflict of interest.

Funding Statement

This research received no external funding.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Crimi C., Cortegiani A. Comment on Liu et al. Application of High-Flow Nasal Cannula in COVID-19: A Narrative Review. Life 2022, 12, 1419. Life. 2022;12:1625. doi: 10.3390/life12101625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bonnesen B., Jensen J.-U.S., Jeschke K.N., Mathioudakis A.G., Corlateanu A., Hansen E.F., Weinreich U.M., Hilberg O., Sivapalan P. Management of COVID-19-Associated Acute Respiratory Failure with Alternatives to Invasive Mechanical Ventilation: High-Flow Oxygen, Continuous Positive Airway Pressure, and Noninvasive Ventilation. Diagnostics. 2021;11:2259. doi: 10.3390/diagnostics11122259. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Life are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES